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ABSTRACT
Objective: The objective of this study was to evaluate in silico and in vitro anticancer activity for synthesized cyclohexane-1,3-dione derivatives.
Methods: The new series of cyclohexane-1,3-dione derivatives were synthesized based on the Michael addition reaction. Further, the structures 
of the synthesized compounds were confirmed by Fourier-transform infrared spectroscopy, 1H nuclear magnetic resonance (NMR), and 13C NMR 
spectral data. Then, the in silico molecular docking studies were carried out using AutoDock tool version 1.5.6 and AutoDock version 4.2.5.1 docking 
program. The antimicrobial activity was carried out using the agar disk diffusion method, and the in vitro anticancer activity was performed by 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for the synthesized compound.
Results: In silico docking study, compound 5c showed good binding score and binding interactions with selected bacterial proteins and breast cancer 
protein. Further, compound (5a-5h) was tested for their antimicrobial activity and compound 5c was only tested for anticancer activity (human breast 
adenocarcinoma 3,4-methylenedioxyamphetamine-MB-231 cell line). Compound 5c was found to be the most active one of all the tested compounds. 
In the MTT assay compound, 5c showed the LC50 value of 10.31±0.003 µg/ml. In antimicrobial activity, the minimum inhibitory concentration of 
compound 5c is 2.5 mg/ml.
Conclusion: An efficient synthesis of biologically active cyclohexane-1, 3-dione derivatives has been developed.
Keywords: Dimedone, Antimicrobial activity, Antifungal activity, Molecular docking studies, Anticancer activity, 3,4-methylenedioxyamphetamine-
MB-231 cell line.
INTRODUCTION
Cancer is one of the most stressful and life aggressive diseases which 
implements cruel deaths in the world [1]. It exhibits at least 100 different 
disease conditions which shares several common symptoms. Cancer 
is the second leading cause of death in developed countries in spite of 
its prevention, early detection, and novel therapies. The World Health 
Organization has warned that nearly 13.1 million people may die of 
cancer in 2030. Among the women community, breast cancer is the most 
prevalent type of cancer [2]. The breast cells spread over the body by a 
process called cancer metastasis. By this process, the organs such as the 
liver, lungs, brain, and bones get affected and it becomes a major problem 
affecting the survival of cancer patients. Many therapies were introduced 
in the recent past to deal with the recurrence of cancer even though drugs 
and medicines have serious side effects. Hence, the development of drugs 
to serve as chemoprevention agents is warranted [3].
Heterocyclic compounds play a vital role in the development of 
pharmacologically active molecules and organic materials [4,5]. The 
hydroxyl carbonyl compounds prepared by the Claisen-Schmidt reaction 
between aldehydes and ketone also play an important role in synthetic 
organic chemistry [6]. Chalcone is a captivating moiety which consists 
of two aromatic rings linked by enone bridge and it belongs to the 
flavonoid family. Chalcones show various pharmacological activities 
such as anticancer, antiviral, antibacterial [7], and antifungal activity [8]. 
The C-C bond formation has been discovered in the past decades and its 
applications were reviewed [9-14]. Reactions such as Knoevenagel [15], 
Henry [16], Aldo [17], and Michael reaction [18] are base catalyzed 
transformations and are mostly used in organic synthesis. Further, 
heterocyclic compounds exhibited specific activity and are used in the 
treatment of many infectious diseases. Liu et al. developed successfully 
an efficient Michael addition between dimedone and cinnamons 
using unmodified chiral diphenylethylenediamine (DPEN) [19]. In the 
fight against the resistant bacterial strains, one of the strategies is the 
development of new antibacterial drugs affecting the integrity of the 
bacterial cell wall . According to that,  many number of chalcones were 
evaluated for their anticancer and antibacterial activity. Studies on 
cyclohexane-1,3-dione remain scattered. Hence, this prompted as to 
undertake the present work. The antibacterial activity of cyclo-hexanone 
1,3-dione compounds  mechanism were done by in silico method.
Modern drug design process helps to identify and develop new 
ligands with a high binding affinity toward a target protein receptor. 
The molecular docking approaches help to reveal drug-receptor 
interaction to a greater detail. The study of receptor-ligand interaction 
is considered as one of the fundamental approaches for rational drug 
design and so the prediction of such interactions by molecular docking 
has been gaining importance [20].
The cyclohexane-1,3-dione derivatives have been synthesized by 
Michael addition method and characterized [21]. The new derivatives 
of cyclohexane-1,3-dione were synthesized and characterized by 
Fourier-transform infrared spectroscopy (FT-IR), 1H nuclear magnetic 
resonance (NMR), and 13C NMR spectral data. Molecular docking 
studies were carried out against bacterial proteins (1UAG, 3UDI, and 
2X5O) and cancer proteins (2ZOQ). Finally, the synthesized compounds 
were screened for antimicrobial activity by agar disk diffusion 
method and in vitro anticancer activity by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay method by 
3,4-methylenedioxyamphetamine (MDA)-MB-231 cell line.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i3.30481
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METHODS
Dimedone (25 g) was purchased from Sigma-Aldrich. The melting 
points of compounds were determined to open capillary method and 
the values were uncorrected. The FT-IR spectrum (cm−1) was recorded 
through KBr in FT-IR spectrometer (model Shimadzu 8400s) in the 
range of 400–4000 cm−1. The 1H and 13C NMR spectra were recorded 
by Bruker 400 MHz spectrometer, and chemical shifts are recorded in 
value (ppm) with tetramethylsilane as an internal standard, as well as 
CDCl3 used as a solvent.
General procedure for the synthesis of (E)-3-(phenyl)-1-(biphenyl-
2-yl) 3-arylprop-2-en-1-one derivatives (3a-3h)
0.1 mol of various substituted aromatic aldehydes (1a-1h) and 0.1 mol 
of 4-acetyl biphenyl (ketone) were taken in a 100 ml beaker, and to this, 
approximately added 30 ml of ethanol containing 2 g of NaOH pellets. 
Then, the mixture was stirred well for 3 h in an ice cold bath after it was 
poured into the crushed ice containing 500 ml beaker and this reaction 
mixture was kept into overnight at room temperature. The chalcone 
precipitated out as solid. Then, it was filtered, dried, and recrystallized 
from ethanol. The purity of the compound was checked by thin-layer 
chromatography (TLC) using CHCl3 as a solvent [22].
General procedure for the synthesis of cyclohexane-1,3-dione 
derivatives (5a-5h)
The dimedone (0.1 mol) and chalcones 3a-3h (0.1 mol) were taken 
in a round bottom flask containing 30 ml ethanol. After, 1 mole of 
sodium acetate was added. Then, this reaction mixture was stirred and 
refluxed for 42 h. After the reaction mixture was poured into 500 ml 
beaker containing crushed ice and it was kept in overnight at room 
temperature. Then, it was filtered, dried, and recrystallized from 




Molecular docking studies have been carried out using the AutoDock 
tools (ADT) version 1.5.6 and AutoDock version 4.2.5.1 docking 
program.
Preparation of the protein
The bacterial proteins and cancer protein were downloaded from 
Protein Data Bank (PDB) with id: 1UAG, 3UDI, 2X5O, and 2ZOQ.
Ligand preparation
Two-dimensional (2D) structure of the cyclohexane-1,3-dione 
derivatives is drawn using ChemDraw Ultra 8.0 (Chemoffice2002). 
After that, the chem 3D ultra were used to convert the 2D structure to 
3D structure of the compounds, and the energy is minimized using the 
semi-empirical AM1 method. All the structures are saved as PDB file 
format for input to ADT. Finally, all the ligand structures are saved as 
PDB file format to carry out docking molecular docking in AutoDock 
Vina.
Grid formation
A grid box with a dimension of 40 × 40 × 40 A3 in 0.375 A spacing and 
centered on 30.473, 47.997, and 9.563 has created around the binding 
site of protein using ADT. The center of the box was set at ligand center 
and grid energy calculations have been carried out.
Docking protocol
Default parameters have been used for auto dock calculations. The 
energy calculation is done using genetic algorithms. The outputs are 
exported to Chimera 1.10 and Discovery Studio 4.5 for visual inspection 
of the binding modes and interaction of the compounds with amino acid 
residues in the active site [23].
Antimicrobial activity
The newly synthesized cyclohexane-1,3-dione compounds have been 
evaluated for their antimicrobial activity. The dimethyl sulfoxide was 
used as the solvent control of this activity. These studies were carried 
out by the agar disk diffusion method.
Anticancer activity
MTT assay
MDA-MB-231 (human breast adenocarcinoma) cell was initially 
procured from the National Center for Cell Science, Pune, India, and 
maintained Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma 
Aldrich, USA).
The cell line was cultured in 25 cm2 tissue culture flask with DMEM 
supplemented with 10% fetal bovine serum, L-glutamine, and sodium 
bicarbonate (Merck, Germany) and an antibiotic solution containing 
penicillin (100 U/ml), streptomycin (100 µg/ml), and amphotericin B 
(2.5 µg/ml). Cultured cell lines were kept at 37°C in a humidified 5% 
CO2 incubator (NBS Eppendorf, Germany).
The viability of cells was evaluated by direct observation of cells by 
inverted phase contrast microscope and followed by MTT assay method.
Cell seeding in 96-well plate
Two-day-old confluent monolayer of cells trypsinized and the cells 
were suspended in 10% growth medium, and 100 µl cell suspension 
(5×104 cells/well) was seeded in 96-well tissue culture plate and 
incubated at 37°C in a humidified 5% CO2 incubator.
Preparation of compound stock
Nearly 1 mg of sample was weighed and dissolved in 1 ml DMEM using a 
cyclomixer. The sample solution was filtered through 0.22 µm Millipore 
syringe filter to ensure the sterility.
Anticancer evaluation
After 24 h, the growth medium was removed, freshly prepared each 
compound in 5% DMEM was five times serially diluted by two-fold 
dilution (100 µg, 50 µg, 25 µg, 12.5 µg and, 6.25 µg) in 500 µl of 5% 
DMEM, and each concentration of 100 µl was added in triplicates to 
the respective wells and incubated at 37°C in a humidified 5% CO2 
incubator. Non-treated control cells were also maintained.
Anticancer assay by MTT method
About 15 mg of MTT (Sigma, M-5655) was reconstituted in 3 ml PBS 
until completely dissolved and sterilized by filter sterilization. After 
24 h of the incubation period, the sample content in wells was removed 
and 30 µl of reconstituted MTT solution was added to all test and cell 
control wells; the plate was gently shaken well and then incubated at 
37°C in a humidified 5% CO2 incubator for 4 h. After the incubation 
period, the supernatant was removed and 100 µl of MTT solubilization 
solution (dimethyl sulfoxide, Sigma-Aldrich, USA) was added, and 
the wells were mixed gently by pipetting up and down to solubilize 
the formazan crystals. The absorbance values were measured using 
microplate reader at a wavelength of 540 nm [24].




    
Mean OD 100% of viability




In the present research work, the new series of cyclohexane-1,3-dione 
derivatives (5a-5h) were synthesized, which is shown in Scheme 
1. The first step in Scheme 1 is the condensation reaction between 
substituted aldehydes and 4-acetyl biphenyl in the presence of a base 
to give compound (3a-3h). Finally, the compounds were recrystallized 
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by using ethanol solvent. The chalcones (3a-3h) react with dimedone 
in the presence of sodium acetate by Michael addition reaction to 
give cyclohexane-1,3-dione derivatives. The cyclohexane-1,3-dione 
derivatives were purified by column chromatography using CHCl3 as 
the solvent. The structure of the synthesized compounds (5a-5h) was 
confirmed by spectral techniques such as FT-IR, 1H NMR, and 13C NMR. 
The possible mechanism for this reaction is shown in Scheme 2.
5, 5-dimethyl-2-(3-oxo-1-diphenyl-3-phenylpropyl) cyclohexane-
1,3-dione (5a)
Yield 69%; white solid; molecular formula; C29H28O3; IR (KBr): 
C=0 (1705.07, 1678.07, 1598.99), 3059.10, 3034.03, 2956.87 (Ar-
CH), 1487.12 (C=C), 694.37, 729.09, 759.95, 833.25; 1H NMR (CDCl3, 
400 MHz): 1.032 (s, 3H), 1.096 (s, 3H), 2.405–2.448 (m, 4H, H-6 and 
H-8); 2.57 ppm (dd, J2’a,2’b=15.2Hz, J2’a,3’=3.2, 1H, H-2’a); 3.64 ppm 
Scheme 1: Synthetic pathway for cyclohexane-1,3-dione derivatives (5a-5h)
Scheme 2: Possible mechanism for the formation of cyclohexane-1,3-dione derivatives (5a-5h)
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(dd, J2’b, 2’a=15.8 Hz, J2’b,3’=3.8 Hz, 1H, H-2’b); 4.41 ppm (dd, J3’,2’a=7 Hz, 
J3’,2’b=4.6 Hz, H-3’); 7.259–7.958 (m, Ar-H). 13C NMR, (CDCl3, 100 MHz); 
30.539 (CH3) at C-5, 30.639 (CH3) at C-5, 38.952 (C-5), 26.076 (C-3’), 
45.724 (C-2’), 52.518 (C-4), 53.387 (C-6), 100.361 (C-2), 196.638 (C-1’), 
202.815 (C-3), 203.895 (C-1), Ar-C (127.247–129.199), IPSO carbon 
(146.232, 139.742, 136.985, 134.892).
2 - ( 1 - ( 4 - c h l o r o p h e n y l ) - 3 - o x o - 3 - d i p h e n y l p r o p y l ) - 5 , 
5-dimethylcyclohexane-1,3-dione (5b)
Yield 86%; white solid; molecular formula; C29H27ClO3; IR (KBr): 
C=0 (1701.22, 1600.92, 1556.55), 3057.17, 3034.03, 2958.80 (Ar-CH), 
1489.05 (C=C), 698.23, 758.02, 833.25; 1H NMR (CDCl3, 400 MHz): 0.978 
(s, 3H), 1.016 (s, 3H), 2.419–2.462 (m, 4H, H-6 and H-8); 2.58 ppm (dd, 
J2’a,2’b=14.8 Hz,J2’a,3’=3.6 Hz, 1H, H-2’a); 3.64 ppm (dd, J2’b, 2’a=16.6 Hz, 
J2’b, 3’=2.6 Hz, 1H, H-2’b); 4.38 ppm (dd, J3’,2’a=7.6 Hz, J3’,2’b=4.4 Hz, H-3’); 
7.259–7.958 (m, Ar-H). 13C NMR, CDCl3, 400 MHz, ẟ; 30.497 (CH3), 30.669 
(CH3), 31.162 (C-5), 26.049 (C-3’), 44.998 (C-2’), 52.461 (C-4), 53.334 
(C-6), 116.542 (C-2), 196.358 (C-1’), 201.749 (C-1), 202.522 (C-3), Ar-C 
(127.157–135.475), IPSO carbon (146.851, 146.401, 140.533, 139.683).
2-(1-(4-bromo phenyl)-3-oxo-3-diphenylpropyl)-5, 5-dimethyl 
cyclohexane-1,3-dione (5c)
Yield 84%; white solid; molecular formula; C29H27BrO3; IR (KBr): 
C=0 (1703.14, 1598.99, 1550.77), 3024.38, 2956.87 (Ar-CH), 1485.19 
(C=C), 696.30, 725.23, 761.88, 835.18; 1H NMR (CDCl3, 400 MHz): 0.879 
(s,3H), 1.255 (s, 3H), 2.422–2.465 (m, 4H, H-6 and H-8), 2.58 ppm (dd, 
J2’a,2’b=15.2 Hz,J2’a,3’=3.2 Hz, 1H, H-2’a); 3.63 ppm (dd, J2’b,2’a=18.9 Hz, 
J2’b,3’=3.9 Hz, 1H, H-2’b); 4.37 ppm (dd, J3’,2’a=7.4 Hz, J3’,2’b=4.2 Hz, H-3’); 
7.234–7.950 (m, ph-H). 13C NMR, (CDCl3, 400 MHz), ẟ; 30.686 (CH3) 
at C-5, 30.503 (CH3) at C-5, 38.884 (C-5), 26.059 (C-3’), 45.040 (C-2’), 
52.444 (C-4), 53.323 (C-6), 100.093 (C-2), 196.322 (C-1’), 202.531 
(C-1), 203.522 (C-3), Ar-C (122.331–131.889), IPSO carbon (146.412, 
139.677, 135.980, 134.696).
2-(1-(2-bromo phenyl)-3-oxo-3-diphenylpropyl)-5, 5-dimethyl 
cyclohexane-1,3-dione (5d)
Yield 78%; white solid; molecular formula; C29H27BrO3; IR (KBr): 
C=0 (1705.07, 1691.57, 1598.99), 2954.95, 2922.16 (Ar-CH), 1481.33 
(C=C), 694.37, 731.02, 765.74, 839.03; 1H NMR (CDCl3, 400 MHz): 1.116 
(s,3H), 1.159 (s, 3H), 2.354–2.476 (m, 4H, H-6 and H-8), 2.58 ppm (dd, 
J2’a,2’b=19.4 Hz, J2’a,3’=3.8 Hz, 1H, H-2’a), 3.61 ppm (dd, J2’b,2’a=18.4 Hz, 
J2’b,3’=3.6 Hz, 1H, H-2’b); 4.92 ppm (dd, J3’,2’a=8.4 Hz, J3’,2’b=3.2 Hz, H-3’); 6.863–
7.892 (m, ph-H). 13C NMR, (CDCl3, 400 MHz); 28.608 (CH3) at C-5, 30.745 
(CH3) at C-5, 38.884 (C-5), 27.869 (C-3’), 42.347 (C-2’), 43.420 (C-4), 50.780 
(C-6), 116.134 (C-2), 197.565 (C-1’), 200.473 (C-1), 203.589 (C-3), Ar-C 
(123.745–131.512), IPSO carbon (146.120, 134.814, 132.107, 131.910).
2-(1-(4-dimethylamino phenyl)-3-oxo-3-diphenylpropyl)-5, 
5-dimethylcyclohexane-1,3-dione (5e)
Yield 70%; white solid; molecular formula; C31H33NO3; IR (KBr): 
C=0 (1676.14, 1662.85, 1516.05), 3026.31, 2953.02 (Ar-CH), 1458.18 
(C=C), 692.44, 738.74, 759.95, 819.75; 1H NMR (CDCl3, 400 MHz): 1.012 
(s,3H), 1.049 (s, 3H), 2.283–2.435 (m, 4H, H-6 and H-8), 2.89 ppm 
(dd, J2’a,2’b=11.8 Hz,J2’a,3’=7.4 Hz, 1H, H-2’a), 3.60 ppm (dd, J2’b, 2’a=6.8 Hz, 
J2’b, 3’=3.6 Hz, 1H, H-2’b); 4.65 ppm (dd, J3’,2’a=7 Hz, J3’,2’b=3.8 Hz, H-3’); 2.525 
(s,3H), 2.5497 (s,3H); 7.197–7.703 (m, Ar-H). 13C NMR, (CDCl3, 400 MHz); 
27.857 (CH3) at C-5, 28.250 (CH3) at C-5, 33.455 (C-5), 22.145 (C-3’), 46.143 
(C-2’), 54.070 (C-4), 56.823 (C-6), 108.423 (C-2), 195.565 (C-1’), 201.763 
(C-1), 202.489 (C-3), 40.717 (CH3) at N(CH3)2, 40.860 (CH3) at N(CH3)2, Ar-C 
(112.295–129.512), IPSO carbon (149.005, 146.421, 139.766, 135.115).
2-(1-(4-fluorophenyl)-3-oxo-3-diphenylpropyl)-5, 5-dimethyl 
cyclohexane-1,3-dione derivative (5f)
Yield 74%; white solid; molecular formula; C29H27FO3; IR (KBr): 
C=O (1681.43, 1698.39, 1703.69), 3058.41 (Ar-CH), 1463.72 (C=C), 
687.90, 712.40, 740.38, 803.17; 1H NMR (CDCl3, 400 MHz): 1.093 
(s,3H), 1.068 (s,3H), 2.273–2.439 (m, 4H, H-6 and H-8), 2.75 ppm (dd, 
J2’a,2’b=11.6 Hz, J2’a,3’=7.1 Hz, 1H, H-2’a); 3.67 ppm (dd, J2’b,2’a=7.3 Hz, 
J2’b,3’=3.8 Hz, 1H, H-2’b); 4.61 ppm (dd, J3’,2’a=7.5 Hz, J3’,2’b=3.6 Hz, H-3’); 
6.893–7.719 (m, Ar-H). 13C NMR, (CDCl3, 400 MHz); 27.38 (CH3) at C-5, 
29.71 (CH3) at C-5, 32.13 (C-5), 23.739 (C-3’), 41.016 (C-2’), 55.910 
(C-4), 58. 711 (C-6), 114.810 (C-2), 198.513 (C-1’), 203.901 (C-1), 




Yield 77%; white solid; molecular formula; C29H27NO5; IR (KBr): C=O 
(1699.17, 1703.82, 1598.41), 3089.51, 2086.61 (Ar-CH), 1489.07 
(C=C), 683.81, 724.23, 759.32, 855.69; 1H NMR (CDCl3, 400 MHz): 0.936 
(s,3H), 1.170 (s,3H), 2.419-2.460 (m, 4H, H-6 and H-8), 2.59 ppm (dd, 
J2’a,2’b=15.4 Hz, J2’a,3’=3.7 Hz, 1H, H-2’a); 3.67 ppm (dd, J2’b, 2’a=18.3 Hz, 
J2’b,3’=3.7 Hz, 1H, H-2’b); 4.51 ppm (dd, J3’,2’a=7.1 Hz, J3’,2’b=4.3 Hz, H-3’); 
7.137–7.943 (m, Ar-H). 13C NMR, (CDCl3, 400 MHz), δ, 31.684 (CH3) 
at C-5, 31.592 (CH3) at C-5, 39.730 (C-5), 27.941 (C-3’), 44.142 (C-2’), 
54.041 (C-4), 55.767 (C-6), 112.42 (C-2), 195.672 (C-1’), 201.337 (C-1), 




Yield 82%; white solid; molecular formula; C29H27ClO3; IR (KBr): 
C=0 (1699.24, 1607.83, 1554.55), 3087.83, 3013.90, 2986.41 (Ar-CH), 
1486.20 (C=C), 694.01, 763.03, 85409; 1H NMR (CDCl3, 400 MHz): 0.971 
(s,3H), 1.013 (s, 3H), 2.407-2.493 (m, 4H, H-6 and H-8), 2.57 ppm (dd, 
J2’a,2’b=14.3 Hz, J2’a,3’=3.1 Hz, 1H, H-2’a); 3.61 ppm (dd, J2’b,2’a=16.7 Hz, 
J2’b,3’=3.1 Hz, 1H, H-2’b); 4.47 ppm (dd, J3’,2’a=7.4 Hz, J3’,2’b=4.9 Hz, H-3’); 
7.194–7.938 (m, Ar-H). 13C NMR, CDCl3, 400 MHz, δ; 30.731 (CH3), 
30.971 (CH3), 31.738 (C-5), 26.072 (C-3’), 45.988 (C-2’), 51.653 (C-4), 
53.413 (C-6), 117.40 (C-2), 196.19 (C-1’), 201.028 (C-1), 203.627 (C-
3), Ar-C (123.740–134.891), IPSO carbon (145.937, 143.970, 140.71, 
139.99).
Docking studies of cyclohexane-1, 3-dione derivatives (5a-5h)
In the present study, in silico molecular docking studies of cyclohexane-
1,3-dione derivatives (5a-5h) against bacterial proteins (PDB id: 
1UAG, 3UDI, and 2X5O) and breast cancer protein (PDB id: 2ZOQ) 
have been carried out using ADT version 1.5.6 and AutoDock 
version 4.2.5.1 docking program. The molecular docking studies are 
reported in terms of binding affinity score and the compound which 
have a better interactions had a lower affinity score. In the ligand, 
cyclohexane-1,3-done derivatives (5a-5h) were individual, docked 
with bacterial proteins. Docking results are shown in Table 1. From 
the table, cyclohexane-1,3-dione derivatives (5a-5h) exhibit good 
docking scores compared to standard drug (amoxicillin). Based on the 
docking score, hydrophobic and hydrophilic interaction, cyclohexane-
1,3-dione derivatives (5a-5h) show better binding affinity compared to 
the standard drug. The proteins IUAG, 3UDI, and 2X5O were involved 
in the cell wall synthesis mechanism. Molecular docking studies show 
that this cyclohexane-1,3-dione derivatives bind well in the active site 
pocket of bacterial proteins and interact with the active site of amino 
acid residues. The best compound of this cyclohexane-1,3-dione 
derivatives has been explained.
Binding affinity value
Finally, the binding affinity value, conventional hydrogen bond, 
hydrophobic interaction such as alkyl and pi-alkyl interactions, and 
other interactions were obtained. Cyclohexane-1, 3-dione derivatives 
showed good interaction with the studied proteins. Compound 
5c showed good binding score with 1UAG (−9.3 kcal/mol), 3UDI 
(−9.6 kcal/mol), and 2X50 (−9.4 kcal/mol) compared with other 
synthesized compound of this series (5a-5h) and standard drug. 
Other synthesized compounds (5a-5h) binding affinity score are 
shown in Table 1.
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Conventional hydrogen bond interaction
Based on high binding affinity value, compound 5c has two conventional 
hydrogen bond interactions (LEU A: 416 and SER A: 415) with carbonyl 
moiety of the biphenyl ring (1UAG); compound 5c has no hydrogen bond 
interaction with 3UDI protein; compound 5c has only one hydrogen 
bond interaction (ASN A: 211) with carbonyl moiety of the biphenyl 
ring (2X5O). Other synthesized compounds (5a-5h) conventional 
hydrogen bond interactions are shown in Table 1.
Hydrophobic interaction
Based on high binding affinity value, compound 5c has five hydrophobic 
interactions LEU A: 416, PRO A: 41, ALA A: 414, ARG A: 186, and 
PHE A: 161 with 1UAG protein; compound 5c has four conventional 
hydrogen bond interactions LYS A: 137, ILE A: 148, PHE A: 72, and 
ILE A: 140 with 3UDI protein; compound 5c has three hydrophobic 
interactions ALA A: 328, VAL A: 232, and HIS A: 267 with 2X5O protein. 
Other synthesized compounds (5a-5h) hydrophobic interactions are 
shown in Table 1. 2D and 3D images of compound 5c are shown in Fig. 1.
The new series of cyclohexane-1,3-dione derivatives (5a-5h) were 
subjected to molecular docking studies against breast cancer protein 
2ZOQ. Compound 5c has high binding affinity score than other 
cyclohexane-1,3-dione derivatives of this series. For that reason, 
that compound was performed in vitro anticancer activity against 
Fig. 1: (a) Two-dimensional (2D) and three-dimensional (3D) images of compound 5c docked with 1UAG protein. (b) 2D and 3D images of 
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MDA-MB-231 cell line. In the ligand, cyclohexane-1,3-dione derivative 
(5a-5h) values are shown in Table 2. 2D and 3D images of compound 5c 
are shown in Fig. 2. Compound 5c showed one conventional hydrogen 
bond interaction with the same amino acid (ARG A: 41) formed at 
carbonyl group of the biphenyl moiety and dimedone moiety. This 
compound has only one alkyl and pi-alkyl interaction with PRO A: 373 
formed at the benzene ring of biphenyl moiety.
Fig. 3: In vitro anticancer activity screening for compound (5c) at 
low concentration
Table 2: Binding affinity value and the conventional hydrogen 
bond of cyclohexane-1, 3-dione derivatives (5a-5h) against 













Table 3: Antibacterial activity with different strains for 
cyclohexane-1,3-dione derivatives (5a-5h)
S. No. Bacteria Zone of inhibition at 2.5 mg/ml 
(diameter in mm)
5a 5b 5c 5d 5e 5f 5g 5h
1. Staphylococcus aureus 9 8 10 9 10 7 9  8
2. Streptococcus pyogenes 12 10 10 10 12 11 12 11
3. Escherichia coli 12 8 9 11 11 11 10 10
4. Pseudomonas sp. 12 7 10 11 11 10 10 9
Table 4: Antifungal activity test for cyclohexane-1,3-dione 
derivatives (5a-5h)
Antimicrobial susceptibility testing against Candida albicans
S. No. Zone of inhibition (diameter in mm)
Compound 10 mg/ml 5 mg/ml 2.5 mg/ml
1. 5a 16 13 mm 12 mm
2. 5b 14 mm 13 mm 11 mm
3. 5c 13 mm 11 mm 9 mm
4. 5d 12 mm 10 mm 9 mm
5. 5e 13 mm 11 mm 10 mm
6. 5f 12 mm 12 mm 10 mm
7. 5g 11 mm 10 mm 11 mm
8. 5h 14 mm 12 mm 10 mm
Fig. 2: Two-dimensional and three-dimensional images of compound 2-(1-(4-bromo phenyl)-3-oxo-3-diphenylpropyl)-5, 
5-dimethylcyclohexane-1,3-dione (5c) docked with 2ZOQ protein
Fig. 4: An in vitro anticancer activity of compound 5c. 
3,4-methylenedioxyamphetamine-MB-231 cells were incubated for 
48 h in the presence of (a) 5c at 6.25 µg/ml, (b) 5c at 12.5 µg/ml, (c) 5c at 
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The synthesized compounds (5a-5h) were subjected to insilico analysis 
against different bacterial proteins (1UAG, 3UDI, 2X5O). Compound 5c 
showed binding scores as −9.4, −9.6, and −9.1 kcal/mol against 1UAG, 
3UDI, and 2X5O proteins indicating a very good affinity. In a similar way 
when these compounds were docked against the human breast cancer 
protein 2ZOQ, compound 5c showed a binding score of −9.6 kcal/mol 
and thereby indicated that it is a good candidate for further studies. 
Hence, in vitro studies (MTT assay of antimicrobial studies) were 
carried out to confirm its activities.
MTT assay study for compound 2-(1-(4-bromophenyl)-3-oxo-3-
diphenylpropyl)-5, 5-dimethyl cyclohexane-1,3-dione derivative
From this result, the in vitro anticancer activity was performed by 
MTT assay method for compound 2-(1-(4-bromophenyl)-3-oxo-3-
diphenylpropyl)-5,5-dimethyl cyclohexane-1,3-dione (5c). Based on 
binding affinity score, the in vitro anticancer activity was done using 
various concentrations (100, 50, 25, 12.5, and 6.25 µg/ml) of the sample 
5c against the MDA-MB-231 cell line. From this result, synthesized 
compound 5c exhibited a good activity at low concentration (6.25 µg/ml). 
The LC50 value of this compound is 10.31±0.003 µg/ml. Experiments 
were conducted in triplicate and the mean value was calculated.
Antimicrobial activity
The new series of cyclohexane-1,3-dione derivatives (5a-5h) were 
screened for antimicrobial activity. The results are shown in Table 3. 
From Table 3, compound 5c showed a good zone of inhibition against 
Staphylococcus aureus, Streptococcus pyogenes, and Pseudomonas sp. 
Compound 5a showed a good zone of inhibition against S. pyogenes, 
Escherichia coli, and Pseudomonas sp. Compound 5b showed a good zone 
of inhibition against S. pyogenes. Compound 5d showed a good zone of 
inhibition against E. coli and Pseudomonas sp. Compound 5e showed 
a good zone of inhibition against S. pyogenes. Compound 5f showed a 
good zone of inhibition against S. pyogenes and E. coli. Compound 5g 
showed a good zone of inhibition against S. pyogenes. Compound 5h 
showed a good zone of inhibition against S. pyogenes. These compound 
values are shown in Table 3.
The cyclohexane-1,3-dione derivatives were screened for antifungal 
activity at different concentrations such as 10, 5, and 2.5 mg/ml. The 
results are shown in Table 4. From Table 4, compound 5a shown the 
good zone of inhibition against Candida albicans (12 mm at 2.5 mg/ml).
CONCLUSION
The new series of cyclohexane-1,3-dione derivatives were synthesized 
by Michal addition reaction. The structures of the cyclohexane-1,3-
dione derivatives were confirmed by FT-IR, 1H, and 13C NMR spectral 
data. The docking study was carried out for cyclohexane-1,3-dione 
derivatives (5a-5h) using bacterial proteins (1UAG, 3UDI, and 2X5O) 
and cancer protein (2ZOQ). From this result, the receptor and the 
compound have greater potency of interactions in a binding site. 
Especially, the compound 5c showed good binding score with cancer 
protein. For that reason, anticancer (human breast adenocarcinoma) 
activity was studied only compound 5c. The LC50 value of compound 5c 
is 10.3134 µg/ml. Furthermore, antimicrobial studies were carried out 
for cyclohexane 1,3-dione derivatives (5a-5h). From the antimicrobial 
and antifungal screening, it was observed that all compounds exhibited 
good activity against Gram-positive and Gram-negative strains. The 
present research work could be useful to develop the in vivo studies of 
the synthesized compounds.
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